Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib real-world postoperative adjuvant study in hepatocellular carcinoma
ChiCTR1900024399Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Qinzhou
- Start
- Jul 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by The First People's Hospital of Qinzhou. Primary endpoint: Progression-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR1900024399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024399.